MacroGenics

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company has established itself as a leader in next-generation protein design and antibody engineering.

The company leverages multiple proprietary technology platforms to generate its pipeline of product candidates, including Fc-engineered antibodies, bispecific DART molecules, and antibody-drug conjugates (ADCs). MacroGenics has a proven track record of success, having advanced three novel therapeutics to FDA approval: MARGENZA and ZYNYZ for the treatment of cancer, and TZIELD for individuals with early-stage Type 1 diabetes. The company has also formed strategic collaborations with global pharmaceutical and biotechnology companies to develop and commercialize novel therapeutics.

With a diverse portfolio spanning oncology, hematology, and autoimmune applications, MacroGenics continues to advance multiple clinical trials and preclinical programs. The company's innovative approaches include bispecific checkpoint antibodies, next-generation T-cell engagers, and targeted ADC therapies designed to improve patient outcomes.